Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Inclusion Criteria:

1. Non-Hodgkin's lymphoma (NHL) confirmed by histopathology, preferably in the detection of tumor tissue PD-L1 expression.
2. A recurrent or refractory disease defined as: 1) recurrence of disease after complete remission (CR); or 2) partial remission (PR), disease stabilization (SD), or disease Progress (PD) when the treatment is completed prior to enrollment in the study.
3. Age≥18 years old, both men and women.
4. The ECOG score is 0-2.
5. There is at least one evaluable lesion (maximum diameter\>15mm or shortest diameter\>10mm). Preferably, PET-CT shows high metabolism of FDG.
6. Have received appropriate first-line and more-line treatment of the corresponding NHL.
7. Liver and kidney function: blood bilirubin≤35μmol/L, AST or ALT is less than 2 times the upper limit of normal value, serum creatinine≤150μmol/L.
8. The thyroid function is normal.
9. Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraception during treatment.
10. Subjects must sign an informed consent form.

Exclusion Criteria:

1. Age\<18 years old；
2. Received ASCT within 90 days prior to the first use of the study drug;
3. Severe allergies, or patients known to be allergic or intolerant of the drug components of the chemotherapy regimen;
4. Active, unrecognized or suspected autoimmune disease, or a history of autoimmune disease within 2 years;
5. Previously exposed to any antibody against PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4
6. Exposure to any study drug within 4 weeks prior to the first use of the study drug
7. Expose to the last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy or arterial embolization) within 3 weeks prior to the first use of the study drug.
8. Have a history of oncology and have received any treatment for this tumor in the past 3 years;
9. Patients during pregnancy and lactation;
10. Accompanied by severe heart disease, including acute myocardial infarction within 6 months, or in accordance with New York Heart Association cardiac function III or IV;
11. A serological test for HIV or active hepatitis C virus is known to be positive;
12. Hepatitis B virus carriers or hepatitis B virus DNA positive untreated patients are known;
13. TB patients active period
14. Other circumstances that the investigator believes are not suitable for inclusion.